English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/63028
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Similarities, differences and agonisms of pleiotropic effects of statins and omega-3 fatty acids | Similitudes, diferencias y agonismos en los efectos pleiotrópicos de las estatinas y los ácidos grasos omega-3

AuthorsVillalobos, M. E.; Sánchez-Muniz, F. J.; Acín, M. T.; Vaquero, M. Pilar ; Higueras, F. J.; Bastida, Sara
Issue Date2010
PublisherAula Médica Ediciones
CitationNutricion Hospitalaria 25: 889- 909 (2010)
AbstractThis paper compares the pleiotropic effects of statins and omega-3 fatty acids (n-3 PUFA) in treating and preventing cardiovascular disease (CVD) and deals with the possible interactions of those compounds. Statins represent one of the most important discoveries to have been made in the field of cardiovascular medicine in recent decades. Their beneficial cardiovascular effects, which have reduced the number of fatal events in patients with atherosclerosis, encompass more than their ability to lower cholesterol levels. The pleiotropic effects of statins involve their anti-inflammatory and antiplatelet properties and their ability to normalize endothelial function. In addition, these drugs may display antiarrhythmic activity, improve insulin sensitivity and counteract hypertension and obesity. The low rate of coronary disease documented in Eskimos corroborates the cardioprotective effects of the n-3 PUFA eicosapentaenoic (EPA) and docosahexaenoic acids beyond their hypolipemic effects. The reduction of CVD-related deaths attributable to the action of α-linolenic fatty acid appears to be related to its strong antiarrhythmic properties. In addition, as a precursor of EPA and this last fatty acid of thromboxane A3, prostacyclin I3, serie-3 prostaglandines and serie 5- leukotrines and inhibitor/modulator of thromboxane A2, prostacyclin I2, serie-2 prostaglandines and serie 4- leukotrienes formation, the α-linolenic acid may reduce inflammation and thrombogenesis. As results of some studies suggest that the combined use of statins and n-3 PUFA improves cardiovascular protection and reduces the CVD-related mortality rate; the paper also reviews the possible synergism between both groups of compounds on CVD treatment and concludes that clear benefits may be obtained.
URIhttp://hdl.handle.net/10261/63028
DOI10.3305/nh.2010.25.6.4819
Identifiersdoi: 10.3305/nh.2010.25.6.4819
issn: 0212-1611
e-issn: 1699-5198
Appears in Collections:(ICTAN) Artículos
Files in This Item:
File Description SizeFormat 
Similitudes, diferencias y agonismos en los efectos pleiotrópicos.pdf188,07 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.